Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
How did ZLAB's recent EPS compare to expectations?
The most recent EPS for Zai Lab Limited is $-0.05, beating expectations of $-0.04.
How did Zai Lab Limited ZLAB's revenue perform in the last quarter?
Zai Lab Limited revenue for the last quarter is $-0.05
What is the revenue estimate for Zai Lab Limited?
According to 4 of Wall street analyst, the revenue estimate of Zai Lab Limited range from $114.07M to $100.83M
What's the earning quality score for Zai Lab Limited?
Zai Lab Limited has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Zai Lab Limited report earnings?
Zai Lab Limited next earnings report is expected in 2026-08-05
What are Zai Lab Limited's expected earnings?
Zai Lab Limited expected earnings is $106.44M, according to wall-street analysts.
Did Zai Lab Limited beat earnings expectations?
Zai Lab Limited recent earnings of $99.61M beat expectations.